Cargando…
Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19
Autores principales: | Gould, A., Muse, A., Thomson, A., McGrane, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal College of Radiologists. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833935/ http://dx.doi.org/10.1016/j.clon.2022.11.028 |
Ejemplares similares
-
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
por: Ng, Kenrick, et al.
Publicado: (2020) -
Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis
por: Ko, Gilbert Chao, et al.
Publicado: (2022) -
Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
por: Thomas, Christian, et al.
Publicado: (2021) -
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
por: Hall, F., et al.
Publicado: (2019) -
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
por: Reichert, Zachery R., et al.
Publicado: (2021)